|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
These statistical data suggest that Thr209Arg in exon 4 of the TRAIL-R1 gene may not represent a modifier of susceptibility to cancer</span>.
|
26315998 |
2015 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
These statistical data suggest that Thr209Arg in exon 4 of the TRAIL-R1 gene may not represent a modifier of susceptibility to cancer</span>.
|
26315998 |
2015 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
In summary, our finding suggests that DR4 polymorphism C626G and A683 rather than A1322G are associated with cancer risk in Caucasians.
|
24761920 |
2014 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
The C626G and A1322G polymorphisms are associated with increased cancer risk, but the A683C polymorphism is rarely associated with cancer risk.
|
24492941 |
2014 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The C626G and A1322G polymorphisms are associated with increased cancer risk, but the A683C polymorphism is rarely associated with cancer risk.
|
24492941 |
2014 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
In summary, our finding suggests that DR4 polymorphism C626G and A683 rather than A1322G are associated with cancer risk in Caucasians.
|
24761920 |
2014 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
In summary, this meta-analysis suggests that TRAIL-R1 C626G polymorphism is marginally associated with cancer susceptibility, and both TRAIL-R1 A1322G G allele and A683C C allele are associated with increased risk for cancer.
|
19643596 |
2009 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
In summary, this meta-analysis suggests that TRAIL-R1 C626G polymorphism is marginally associated with cancer susceptibility, and both TRAIL-R1 A1322G G allele and A683C C allele are associated with increased risk for cancer.
|
19643596 |
2009 |
|
Liver carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Combined genotype analysis showed that coinheritance of the polymorphic genotypes of DR4-C626G and -A1322G conferred nine-fold increased risk of HCC (OR, 9.34; 95%CI, 3.76-23.12).
|
30945308 |
2019 |
|
Liver carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
The frequency distribution of rs20575 genotypes showed a statistically significant difference between the two studied groups (P = 0.02), the carriers of the C allele were 2.01 times more likely to develop HCC than the carriers of the G allele (P = 0.003), while no significant difference in rs20576 genotypes distribution was found between the studied groups (P = 0.680).
|
28975649 |
2018 |
|
Liver carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.
|
22401174 |
2012 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The DR-4 haplotype 626C-683C [626C > G, Thr209Arg (rs4871857) and 683A > C, Glu228Ala (rs17088993)] has recently been linked to an increased risk of breast cancer.
|
21484799 |
2012 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
The DR-4 haplotype 626C-683C [626C > G, Thr209Arg (rs4871857) and 683A > C, Glu228Ala (rs17088993)] has recently been linked to an increased risk of breast cancer.
|
21484799 |
2012 |
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Neither Thr209Arg (626C>G) nor Glu228Ala (683A>C) alone were significantly associated with breast cancer risk [odds ratio (OR) = 0.84, 95% confidence interval (CI) = 0.65-1.08, P = 0.18 and OR = 0.89, 95% CI = 0.72-1.12, P = 0.30].
|
15975957 |
2005 |
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Neither Thr209Arg (626C>G) nor Glu228Ala (683A>C) alone were significantly associated with breast cancer risk [odds ratio (OR) = 0.84, 95% confidence interval (CI) = 0.65-1.08, P = 0.18 and OR = 0.89, 95% CI = 0.72-1.12, P = 0.30].
|
15975957 |
2005 |
|
Lymphoma, Follicular
|
|
0.010 |
GeneticVariation
|
BEFREE |
Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.
|
27977511 |
2017 |
|
Head and Neck Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Data obtained through genetic studies has highlighted highly polymorphic nature of DR4 and in accordance with this concept, we investigated the association between Head and Neck Cancer and polymorphisms in TRAIL (1595 C/T) and DR4 (C626G and A1322G) gene.
|
26718429 |
2015 |
|
Malignant Head and Neck Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Data obtained through genetic studies has highlighted highly polymorphic nature of DR4 and in accordance with this concept, we investigated the association between Head and Neck Cancer and polymorphisms in TRAIL (1595 C/T) and DR4 (C626G and A1322G) gene.
|
26718429 |
2015 |
|
Stage III Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DR4 haplotype C rs20575 A rs20576 A rs6557634 represents an important factor accounting the patients susceptibility to GBC probably due to decreased apoptosis.
|
24587306 |
2014 |
|
Cholelithiasis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among these, the DR4 C rs20575 A rs20576 A rs6557634 haplotype emerged as main factor influencing GBC susceptibility as the risk was not modulated by gender or gallstone stratification.
|
24587306 |
2014 |
|
Cholecystolithiasis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among these, the DR4 C rs20575 A rs20576 A rs6557634 haplotype emerged as main factor influencing GBC susceptibility as the risk was not modulated by gender or gallstone stratification.
|
24587306 |
2014 |
|
Gallbladder Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DR4 haplotype C rs20575 A rs20576 A rs6557634 represents an important factor accounting the patients susceptibility to GBC probably due to decreased apoptosis.
|
24587306 |
2014 |
|
Stage IIB Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DR4 haplotype C rs20575 A rs20576 A rs6557634 represents an important factor accounting the patients susceptibility to GBC probably due to decreased apoptosis.
|
24587306 |
2014 |
|
Recession
|
|
0.010 |
GeneticVariation
|
BEFREE |
The C626G polymorphism was associated with slightly elevated cancer risk in recession model comparison [odds ratio (OR)=1.12, 95 % confidence interval (CI)=1.00-1.26, P heterogeneity=0.425].
|
24492941 |
2014 |
|
Stage IIA Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DR4 haplotype C rs20575 A rs20576 A rs6557634 represents an important factor accounting the patients susceptibility to GBC probably due to decreased apoptosis.
|
24587306 |
2014 |